Skip to main content
  • Register
  • Help
  • Contact us

Zymeworks Inc (ZYME) NPV

Sell:$28.57 Buy:$28.89 Change: $1.20 (4.03%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.20 (4.03%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.20 (4.03%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zymeworks Inc. a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins, and EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function. Its lead product candidate is ZW25, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). It product candidate ZW49, combines the design of ZW25 with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker.

Contact details

540-1385 West 8Th Avenue
V6H 3V9
+1 (604) 6781388

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.36 billion
Shares in issue:
46.14 million
New York Stock Exchange
US dollar

Key personnel

  • Lota Zoth
    Chairman of the Board
  • Ali Tehrani
    President, Chief Executive Officer, Co-Founder, Director
  • Neil Klompas
    Chief Financial Officer, Executive Vice President - Business Operations
  • Anthony Polverino
    Executive Vice President - Early Development, Chief Scientific Officer
  • Neil Josephson
    Interim Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.